[EGF receptor blockade with monoclonal antibodis and so-called "small molecules"].
Ciardiello
Fortunato
F
Division of Medical Oncology, Department of Clinical and Experimental Medicine, Seconda Universita di Napoli, Naples, Italy.
Ma
Brigette
B
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects*; D016503:Drug Delivery Systems; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D016032:Randomized Controlled Trials as Topic; D015398:Signal Transduction / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases